<unk>  is indicated for the treatment of adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of Waldenström's macroglobulinemia. It is also indicated for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti-CD20-based regimen.
Zanubrutinib
Acalabrutinib
Tucatinib
Ponatinib
Fostamatinib
Neratinib
Imatinib
Brigatinib